Surgical Endoscopy

, Volume 25, Issue 4, pp 1344–1345 | Cite as

Optimizing locoregional staging in the preoperative setting of resectable esophageal cancer

Letter
  • 55 Downloads

Notes

Acknowledgements

There is no research support for this article.

Disclosures

Charalambos Batsis and Ioannis Makris have no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Erasmus JJ, Munden RF (2007) The role of integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response. Semin Radiat Oncol 17:29–37PubMedCrossRefGoogle Scholar
  2. 2.
    Choi J, Kim SG, Kim JS, Jung HC, Song IS (2010) Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 24:1380–1386PubMedCrossRefGoogle Scholar
  3. 3.
    Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17PubMedCrossRefGoogle Scholar
  4. 4.
    Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16:795–798PubMedCrossRefGoogle Scholar
  5. 5.
    Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360:1362 (author reply 1363)PubMedCrossRefGoogle Scholar
  6. 6.
    Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681PubMedCrossRefGoogle Scholar
  7. 7.
    Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247:714–715PubMedCrossRefGoogle Scholar
  8. 8.
    Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10:33–48PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9:1413–1416PubMedCrossRefGoogle Scholar
  11. 11.
    Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9:389–392PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16:774–775PubMedCrossRefGoogle Scholar
  13. 13.
    Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287PubMedCrossRefGoogle Scholar
  14. 14.
    Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250PubMedCrossRefGoogle Scholar
  15. 15.
    Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545PubMedCrossRefGoogle Scholar
  16. 16.
    Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782Google Scholar
  17. 17.
    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068PubMedCrossRefGoogle Scholar
  18. 18.
    Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRefGoogle Scholar
  19. 19.
    Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28(17):e279–e280; author reply e282–3PubMedCrossRefGoogle Scholar
  20. 20.
    Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7(4):347–350CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Surgery, School of MedicineUniversity of IoanninaIoanninaGreece
  2. 2.Second Surgical Department, “G, Gennimatas” General HospitalAristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations